Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

Key Inclusion Criteria: * Male or female patients 18 years or older * Active NIU, in at least one eye, as defined below, in patients requiring intensification of systemic immunosuppressive therapy; * Vitreous haze at least 1+ on the scale of Nussenblatt et al 1985,or * Chorioretinal lesions due to uveitis (chorioretinal lesions due to infectious uveitis excluded) * Patients with a flare and at the time of the enrollment on systemic corticosteroid or non-steroidal immunosuppressants had their therapy tapered or stopped, respectively, at the time of intravitreal LFG316 administration. Visual acuity (ETDRS method) of 20 letters (20/400 Snellen equivalent) or better in the study eye. * For female patients, must not be pregnant or lactating and must, unless post-menopausal, use effective contraception. * Ability to provide informed consent and comply with the protocol. Key Exclusion Criteria: * Uveitis so severe that, in the investigator's judgment, it was too risky to test an experimental drug * Any biologic immunosuppressive agent given via intravitreal, intravenous or subcutaneous route within 4-12 months depending on the agent. * History of infectious uveitis or endophthalmitis in either eye. * History of retinal detachment * Any intraocular surgery, intravitreal injection, periocular injection, or laser photocoagulation to the study eye within 90 days prior to dosing. * In the study eye, cataract expected to interfere with study conduct or require surgery during the stud…